Sign inJoin waitlistJoin the waitlist

MH

Mohammadali Hamiditabar

Credentials:

History

Residency
2017–2020
Medical School
2013–2017

Research

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience
Pancreas · 2014 · 109 citations
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment
Clinical Nuclear Medicine · 2017 · First of 9 authors · 68 citations
Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors
Clinical Nuclear Medicine · 2017 · First of 6 authors

ED
Ebrahim Delpassand
3 papers
Edward Wolin
2 papers
TO
Thomas O’Dorisio
2 papers
Alireza Mojtahedi
1 paper · 1 as a resident
GV
Gelareh Vahdati
1 paper
JS
Jonathan Strosberg
1 paper
JR
Joseph Roys
1 paper
LK
Larry Kvols
1 paper
SZ
Sara Zamanian
1 paper
Trustin Saam
1 paper · 1 as a resident